All the Active Ingredient Drugs
Estrogen, Progestogen. Ethinylestradiol 0.6 mg, Norelgestromin 6 mg. TRANSDERMAL PATCHES: 3,9. 1st patch on
day 1 of cycle. 1 patch (on same day)/
wk. on day 8 and 15 of cycle. 4th wk
(from day 22) is patch free. New cycle
aft. 7 days patch free. See lit.
Female contraception. Evra is intended for women of fertile age.
Hypersens.
Presence or risk of VTE. Current VTE (on anticoagulants) or history of (e.g. DVT] or PE);Known heredit. or acquir. predisposit. for VT such as: APC-resistan., (includ. Factor V Leiden), antithrombin-III-defic., protein C defic., protein S defic.; Major surg. with prolong. immobilisat.
A high risk of VT due to the presence of multiple risk fact.
Presence /risk of ATE.
Arterial thromboembol. – current ATE , history of ATE (e.g. MI) or prodromal condit. (e.g. angin. p.); Cerebrovasc. dis. – current stroke, history of stroke or prodromal condit. (e.g., TIA); Known heredit. or acquir. predisposit. for ATA such as hyperhomocysteinaemia and APLA. (anticardiolipin-antibodies, lupus anticoagulant); Hist. of migraine with focal neurology. sympt.; A high risk of ATA due to multiple risk fact. or to the presence of one serious risk factor (E.G. diabetes mell. with vascular sympt., sev. hypertens., severe dyslipoproteinaemia.
Known/susp. carcinoma of the breast.
Carcinoma of the endometrium or other known or suspect. oestrogen-depend. neoplasia
Abnorm. liver func. related to acute or chron. hepatocell. dis.
Hepat. adenomas or carcinomas.
Undiagnos. abnorm. gen.bleed.
Concomi. use with the med. products contain. ombitasvir/paritaprevir/ritonavir and dasabuvir.
